AcelRx Pharmaceuticals presented results from its Phase 3 SAP303 study of ARX-04 at the 15th Annual Pain Medicine Meeting of the American Society of Regional Anesthesia and Pain Medicine. Read More »
AzurRx BioPharma has partnered with Mayoly Spindler to begin a Phase II clinical trial to assess the safety and effectiveness of MS1819-SD for the treatment of patients who have exocrine pancreatic insufficiency that is the result of chronic pancreatitis. Read More »
Intrarosa (prasterone), which is designed for women who experience moderate to severe pain during sex, has been approved by the U.S. Food and Drug Administration. Read More »
Boehringer Ingelheim has released data from its Phase I INVICTAN-1 trial involving BI 695502, the company’s bevacizumab biosimilar candidate, which shows that the drug is a bioequivalent of Avastin, which is licensed in the U.S. and E.U. Read More »
The 2016 graduate and undergraduate student winners of the Collegiate Inventors Competition included inventions and innovations presented at the competition including the administration of therapeutic drugs at-home and engineered biological particles that destroy pesticides in residual crops. Read More »
PharmaMar has named Pascal Besman as its new chief operating officer, effective immediately. Read More »
McKesson and Health Mart support the dedication of pharmacists across all practice settings and commend the American Pharmacists Association for celebrating pharmacists’ commitment to provide customers with extraordinary service. Read More »
The Oncologic Drugs Advisory Committee, which is part of the U.S. Food and Drug Administration, has voted that Spectrum Pharmaceuticals' Qapzola has not displayed considerable indication of a more effective treatment compared to placebo for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. Read More »
Array BioPharma and the U.S. Food and Drug Administration have reached an agreement regarding Special Protocol Assessment for Array’s Phase 3 trial for encorafenib and Erbitux called BEACON CRC. Read More »
Ablative Solutions' Investigational New Drug application for the Peregrine System Kit -- a catheter-based renal denervation that targets the delivery of alcohol to treat uncontrolled hypertension -- has been accepted by the U.S. Food and Drug Administration. Read More »
Annals of Oncology published the results of a brand new post-hoc analysis from two Gilotrif Phase II trials that examined dose adjustments for patients suffering from advanced non-small cell lung cancer. Read More »
Valeant Pharmaceuticals International's RELISTOR Tablets are now available for prescriptions in the United States to treat adults with chronic non-cancer pain who are experiencing opioid-induced constipation. Read More »
Zavante Therapeutics, a privately owned biopharmaceutical company that conducts late-stage clinical trials, has appointed eight infectious disease specialists to serve on its newly formed Scientific Advisory Board. Read More »
The National Association of Chain Drug Stores RxIMPACT Votes, a leader in the pharmaceutical industry in motivating voters with outstanding, nonpartisan get-out-the-vote initiatives, is focused on raising voter registration and the interest of politics during their campaigns. Read More »
AcelRx Pharmaceuticals has presented the results from its Phase 3 SAP302 study of ARX-04 by representatives from the company and its investigators. Read More »
Alcon, a worldwide leader in eye care and a Novartis division, has released its Online Toric IOL Calculator, which was developed for the use of cataract surgeons who are treating patients with corneal astigmatism. Read More »
Crown Bioscience, a subsidiary of Crown Bioscience International and a worldwide global drug discovery and development services company that provides translational platforms that improve the research of oncology and metabolic diseases, has named Dr. Jean Pierre Wery its CEO. Read More »
Argentina's regulatory body has approved Hemispherx Biopharma's New Drug Application for the commercial sale of rintatolimod. Read More »
Akebia Therapeutics Inc. and Otsuka Pharmaceutical Co. Ltd. recently entered a collaboration and license agreement in the U.S. for vadadustat, an oral hypoxia-inducible factor stabilizer in development for the treatment of anemia associated with chronic kidney disease Read More »
Mylan N.V. and Biocon Ltd. released results of their Heritage Study in the Journal of the American Medical Association, showing positive indications for MYL-1401O, the proposed biosimilar trastuzumab co-developed by Mylan and Biocon. Read More »
Alerts Sign-up
